A decision-making tool for first-line treatment in advanced non-small-cell lung cancer based on plasma proteome biomarkers

被引：0

作者：

Sela, Itamar

Christopoulos, Petros

Puzanov, Igor

Bar, Jair

Zer, Alona

Moskovitz, Mor

Reinmuth, Niels

Lotem, Michal

Katzenelson, Rivka

Agbarya, Abed

Farrugia, David

Price, Gillian

Cheley, Helen

Abu-Amana, Mahmud

McGregor, Kimberly

Lou, Yanyan

Leibowitz, Raya

Dicker, Adam P.

Carbone, David Paul

Gandara, David R.

机构：

[1] OncoHost LTD, Binyamina, Israel

[2] Heidelberg Univ Hosp, Heidelberg, Germany

[3] Roswell Pk Canc Inst, Buffalo, NY USA

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Rambam Hlth, Haifa, Israel

[6] Davidoff Canc Ctr, Rabin Med Ctr, Beilinson Campus, Petah Tiqwa, Israel

[7] Asklepios Clin Munich Gauting, Thorac Oncol, Gauting, Germany

[8] Hadassah Med Ctr, Jerusalem, Israel

[9] Kaplan Med Ctr, Dept Oncol, Rehovot, Israel

[10] Bnei Tzion Hosp, Haifa, Israel

[11] Gloucestershire Oncol Ctr, Cheltenham, England

[12] NHS Grampian, Aberdeen, Scotland

[13] Swansea Bay UHB, Swansea Bay, Wales

[14] Haemek Med Ctr, Afula, Israel

[15] OncoCyte, Cambridge, MA USA

[16] Mayo Clin, Jacksonville, FL USA

[17] Shamir Med Ctr, Beer Yaagov, Israel

[18] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA

[19] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[20] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9122

引用

页数：1

共 50 条

[1] First-line treatment for advanced non-small-cell lung cancer
Laskin, Janessa J.
Sandler, Alan B.
ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
[2] Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer
Heigener, David F.
Kerr, Keith M.
Laing, Gavin M.
Mok, Tony S. K.
Moiseyenko, Fedor V.
Reck, Martin
CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4881 - 4887
[3] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Gettinger, Scott
Rizvi, Naiyer A.
Chow, Laura Q.
Borghaei, Hossein
Brahmer, Julie
Ready, Neal
Gerber, David E.
Shepherd, Frances A.
Antonia, Scott
Goldman, JonathanW.
Juergens, Rosalyn A.
Laurie, Scott A.
Nathan, Faith E.
Shen, Yun
Harbison, Christopher T.
Hellmann, Matthew D.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
[4] First-line immunotherapy in advanced non-small-cell lung cancer
Noronha, Vanita
Mehta, Prashant
Malik, Prabhat Singh
Patel, Amol
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
[5] Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
Socinski, M. A.
CURRENT ONCOLOGY, 2014, 21 (05) : E691 - E703
[6] Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer
Chow, Helen
Edelman, Martin J.
Giaccone, Giuiseppe
Ramalingam, Suresh S.
Quill, Timothy A.
Bowser, Andrew D.
Mortimer, Jim
Guerra, Wilma
Beckett, Laurel A.
West, Howard L.
Lara, Primo N.
Gandara, David R.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) : 1421 - 1429
[7] Erlotinib in the first-line treatment of non-small-cell lung cancer
D'Arcangelo, Manolo
Cappuzzo, Federico
EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
[8] First-line treatment of advanced ALK-positive non-small-cell lung cancer
Gandhi, Shipra
Chen, Hongbin
Zhao, Yujie
Dy, Grace K.
LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
[9] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
Liam, Chong-Kin
TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
[10] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Kao, Hsiang-Fong
Lin, Chia-Chi
Yang, James Chih-Hsin
FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003

← 1 2 3 4 5 →